XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2021
Summary of Significant Accounting Policies  
Schedule of disaggregation of revenue by major source

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2021

    

2020

    

2021

    

2020

Biopharma/Pharma

$

45,489

$

8,566

$

87,877

$

17,348

Animal Health

 

8,394

 

220

 

17,394

 

447

Reproductive Medicine

2,308

603

4,204

1,368

Total revenues

$

56,191

$

9,389

$

109,475

$

19,163

Schedule of geographical revenues, by origin

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2021

    

2020

    

2021

    

2020

Americas

$

29,135

$

7,403

$

56,870

$

15,087

Europe, the Middle East and Africa (EMEA)

 

15,043

 

1,763

 

29,251

 

3,695

Asia Pacific (APAC)

 

12,013

 

223

 

23,354

 

381

Total revenues

$

56,191

$

9,389

$

109,475

$

19,163

Schedule of net loss per share

The following shows the amounts used in computing net loss per share (in thousands except per share data):

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2021

    

2020

    

2021

    

2020

Net loss

$

(5,389)

$

(5,803)

$

(8,916)

$

(9,746)

Paid-in-kind dividend on Series C convertible preferred stock

 

(2,000)

 

 

(4,196)

 

Net loss attributable to common shareholders

$

(7,389)

$

(5,803)

$

(13,112)

$

(9,746)

Weighted average common shares issued and outstanding - basic and diluted

45,757,532

38,281,087

44,786,403

37,914,818

Basic and diluted net loss per share

$

(0.16)

$

(0.15)

$

(0.29)

$

(0.26)

Schedule of number of shares excluded from the computation of diluted loss per share

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2021

    

2020

    

2021

    

2020

Stock options

 

5,855,953

 

4,536,585

5,908,632

 

4,163,301

Warrants

 

 

190,977

 

186,670

Restricted stock units

339,212

339,212

Series C convertible preferred stock

5,283,411

5,283,411

Convertible senior notes

 

4,810,002

 

4,810,002

4,810,002

 

4,810,002

 

16,288,578

 

9,537,564

16,341,257

 

9,159,973